Juan Carlos Aragón Named VTI CEO and Executive Director

Visioneering Technologies Inc. (VTI) has appointed Dr. Juan Carlos Aragón as CEO and executive director.
 
Aragón has more than 30 years of leadership experience in the vision care industry, includes senior executive positions in several large international vision care companies, and managing divisions for the Americas, Asia Pacific, and Europe.

“We are delighted and extremely fortunate to have Dr. Aragón join the VTI team to help lead the company through the next phase of its growth. With his background leading global businesses, expertise working with myopia management, and extensive experience with the China vision care market, he is ideally suited to propel Visioneering to future success,” VTI Board Chairman Dr. David J. Mazzo said. “JC, as he is known by many, is well-recognized as a leader in the global vision care industry. We expect his reputation and extensive contacts will contribute greatly to creating new opportunities for VTI.”
 
Most recently, Aragón was president of CooperVision (CV) Specialty EyeCare, which incorporates CV’s soft custom and rigid gas permeable contact lens product offerings, including orthokeratology, scleral lenses, and myopia management products for global markets, including China. In the previous 23 years, Aragón has held several senior positions within CooperVision and a predecessor company. He also held positions within CIBA Vision, a predecessor company to Alcon, and with Bausch + Lomb.

Aragón is a former board member and former chair of the Global Myopia Awareness Coalition (GMAC), a diverse group of companies working together to protect children from the effects of myopia. His leadership in and service to GMAC highlights Aragón’s dedication to vision care and the respect the industry has for his capabilities. He also volunteers as board chairman of Optometry Giving Sight; and has been a board member of the Brien Holden Foundation, the International Agency for the Prevention of Blindness, and Vision Aid Overseas (now Vision Action). He was also a board member of Sight Glass Vision, now a Joint Venture of CooperVision and Essilor/Luxottica.

Aragón earned his optometry degree from the Superior School of Medicine of the National Polytechnic Institute in Mexico City.
 
“I have known VTI since its initial commercialization in 2016. In my view, NaturalVue Multifocal is an extraordinary product for managing both myopia and presbyopia,” Aragón stated. “I have been impressed by the success to date of the team at VTI and look forward to working with them to achieve VTI’s full potential in existing markets and new territories, especially in China. With the interim one-year results of the PROTECT Clinical Study to be released in the coming months, I feel fortunate to have the opportunity to take the helm at VTI at this pivotal time for the company.”
 
Visioneering Technologies Inc. merges advanced engineering with a drive to achieve superior results for patients and practitioners. VTI’s flagship product is the NaturalVue (etafilcon A) Multifocal one-Day Contact Lens, an extended depth of focus lens.